Skip to main content
. 2021 Jun 5;13(11):2824. doi: 10.3390/cancers13112824

Figure 4.

Figure 4

Disease-free interval in HER2-low/HR+ versus HER2−/HR+ (A), in HER2-low/HR− versus HER2−/HR− (B), in HER2-low/HR+ versus HER2+/HR+ (C) and in HER2-low/HR− versus HER2+/HR− (D) tumors. Abbreviations: HR: hormone receptor.